American researchers have found that giving a combination of imantanib and a drug that induces cell death was better at inhibiting the growth of Ewing’s sarcoma in mice than either therapy on its own, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague on Friday.
Researchers at the Cancer Treatment Centers of America found that antioxidant therapies such as green tea extract, melatonin, high-potency multivitamins, vitamin C and vitamin E do not interfere with radiation treatment.
New Mayo Clinic research suggests that a shearing injury of the tissue that lines the tendons within the carpal tunnel may cause carpal tunnel syndrome, a debilitating condition of the wrist and hand.
Potentially blinding blood vessel growth in the cornea resulting from eye injury or even surgery can be reduced by more than 50 percent with a new manmade protein, researchers say.
Preliminary results from a phase II clinical trial have provided the first evidence that treating people with kidney cancer with bevacizumab and erlotinib before surgery is safe, effective and may prolong patients’ survival, the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics heard on Thursday.
Researchers investigating ways of prompting the immune system to recognise and kill tumour cells have found that a drug containing parts of the diptheria toxin appears to work well in patients with advanced melanoma, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on Thursday.
Younger women with ovarian cancer have better survival rates than older patients, even if they have surgery to conserve their fertility, added family history of the illness is the most important risk factor and it is influenced by hormones.
IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted a Marketing Authorization Application (MAA) in eCTD format (electronic common technical document) to the European Medicines Agency (EMEA) for Mepact (mifamurtide for injection), requesting approval for its use in the treatment of patients with newly diagnosed resectable high-grade osteosarcoma following surgical resection in combination with post-operative multi-agent chemotherapy. This announcement follows the October 25, 2006 submission of a New Drug Application (NDA) for Junovan (mifamurtide for injection) to the Food and Drug Administration (FDA) in the United States.
Prostate cancer patients who have a temporary rise in their prostate specific antigen (PSA) levels after radiation therapy – called a PSA bounce – are not at an increased risk of their cancer coming back any more than those who don?t have a temporary rise, according to the largest study of its kind presented November 8, 2006, at the American Society for Therapeutic Radiology and Oncology?s 48th Annual Meeting in Philadelphia.
Researchers at the Johns Hopkins Kimmel Cancer Center have for the first time implicated the muscle protein myosin VI in the development of prostate cancer and its spread.